Table 2 Clinical markers of the study participants comparing male and female using a Chi Square test, JUSH, South West Ethiopia, 2009
Characteristics | Male No. (%) | Female No. (%) | Total No. (%) | P - value |
|---|---|---|---|---|
WHO disease stage when HAART started (N = 319) | Â | Â | Â | 0.075 |
I | 7(4.9) | 5(2.9) | 12(3.8) | Â |
II | 35(24.3) | 43(24.6) | 78(24.5) | Â |
III | 85(59.0) | 88(50.3) | 173(54.2) | Â |
IV | 17(11.8) | 39(22.3) | 56(17.6) | Â |
CD4 count when the treatment was started (N = 305) | Â | Â | Â | 0.298 |
≥ 500 | 1(0.7) | 0(0.0) | 1(0.3) |  |
201-499 | 43(30.5) | 44(26.8) | 87(28.5) | Â |
≤ 200 | 97(68.8) | 120(73.2) | 217(71.1) |  |
Recent CD4 count (N = 257) | Â | Â | Â | 0.111 |
≥ 500 | 22(18.5) | 38(27.5) | 60(23.3) |  |
201-499 | 73(61.3) | 82(59.4) | 155(60.3) | Â |
≤ 200 | 24(20.2) | 18(13.1) | 42(16.3) |  |
Duration of treatment in months (N = 319) | Â | Â | Â | 0.877 |
3.0-12.0 | 25(17.4) | 28(16.0) | 53(16.6) | Â |
12.1-24.0 | 35(24.3) | 40(22.9) | 75(23.5) | Â |
≥ 24.1 | 84(58.3) | 107(61.1) | 191(59.9) |  |
Treatment regimen(N = 319) | Â | Â | Â | 0.549 |
d4t (30)- 3TC-NVP | 88(61.1) | 115(65.7) | 203(63.6) | Â |
d4t (40)- 3TC-NVP | 12(8.3) | 14(8.0) | 26(8.2) | Â |
d4t (30)- 3TC-EFV | 21(14.6) | 17(9.7) | 38(11.9) | Â |
d4t (40)- 3TC-EFV | 5(3.5) | 3(1.7) | 8(2.5) | Â |
AZT-3TC-NVP | 16(11.1) | 25(14.3) | 41(12.9) | Â |
AZT-3TC-EFV | 2(1.4) | 1(0.6) | 3(0.9) | Â |